Letrosan

Quick links to important sections

Letrosan

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Letrosan

Quick Facts: Letrosan

Property Description
Active ingredient Letrozole
Form Oral tablet (film-coated)
Pharmacological class Non-steroidal Aromatase Inhibitor
General Purpose Hormonal Modulation
Origin Synthetic triazole derivative

What is Letrosan? Defining the Drug's Identity and Class

Letrosan is a specific brand of prescription-only medicine supplied as an oral tablet, containing the active ingredient Letrozole. It is classified as an Aromatase Inhibitor, placing it within the broader group of antineoplastic and antiestrogen agents. Letrozole is recognized as a third-generation non-steroidal Aromatase Inhibitor because of its synthetic triazole structure and its high specificity for the target enzyme. This identity means the medicine is designed for administration by mouth and is clinically recognized for its focused approach to systemic hormone control.

How Letrosan Works: The Mechanism of Estrogen Suppression

The medication's fundamental action centers on its ability to inhibit the Aromatase enzyme. This enzyme is critical in the body, primarily in peripheral tissues, as it catalyzes the final step in the conversion of androgen hormones into Estrogen. By competitively and reversibly binding to the enzyme, Letrosan drastically suppresses the synthesis of Estrogen throughout the body, leading to a significant reduction in circulating hormone levels. Letrozole works by decreasing the amount of estrogen the body makes.

General Therapeutic Role: The Purpose of Hormonal Modulation

The overarching purpose of Letrosan is to achieve a state of hormonal modulation by establishing a profound, pharmacologically-induced low-estrogen environment. This targeted action is necessary to disrupt estrogen-dependent biological processes that require the presence of the hormone to thrive. The drug serves as a specific targeted hormonal agent, providing a precise means of limiting estrogen's systemic availability and influence, such as in the therapeutic management of hormone-sensitive conditions in postmenopausal women.

Regulatory References

  1. NIH Cancer Drug Information

What side effects are possible with Letrosan?

Possible side effects and safety information

The safety profile of Letrosan (Letrozole) is established through regulatory classifications that organize documented adverse reactions by frequency and affected body systems. These effects are often related to the suppression of estrogen.

Officially Classified Adverse Reactions

Adverse reactions are formally categorized based on the frequency observed in clinical studies:

  • Very Common (Affects 1 in 10 people or more): Hot flushes, arthralgia (joint pain), fatigue (including weakness), increased sweating (hyperhidrosis), and hypercholesterolemia (elevated cholesterol).
  • Common (Affects between 1 in 100 and 1 in 10 people): Headache, dizziness, nausea, bone pain, osteoporosis, bone fracture, depression, diarrhea, constipation, peripheral edema, weight increase, and vaginal hemorrhage.

The regulatory documents group these effects primarily into Musculoskeletal and Connective Tissue Disorders, Metabolism and Nutrition Disorders, and Vascular Disorders.

Serious Adverse Reactions and Constraints

Official labeling documents an increased risk of serious events associated with use. This includes skeletal health risks such as osteoporosis and subsequent bone fractures, which are specifically linked to long-term exposure. The label also notes the potential for serious cardiovascular and cerebrovascular events (such as stroke) and severe hypersensitivity reactions.

Specific Population Restrictions

Letrosan is contraindicated by regulatory authorities for use in women with an unestablished postmenopausal status (premenopausal), in pregnancy, and during lactation. Caution is specifically advised when used in patients with severe hepatic impairment due to potential changes in drug exposure. Additionally, official labeling advises that side effects like dizziness and fatigue may impair the ability to drive or operate machinery.

Overdose and Emergency Response

The official regulatory profile for a Letrosan (Letrozole) overdose is based on limited clinical experience and establishes a strict requirement for seeking emergency care.

Documented Overdose Presentations

The highest reported single dose ingested in overdose circumstances was 62.5 mg (equal to twenty-five 2.5 mg tablets). In these documented cases, official regulatory sources confirm that no serious adverse reactions were observed. Official overdose sections do not detail specific physiological system effects or symptom clusters.

When to Seek Immediate Medical Help

Despite the non-serious nature of these documented outcomes, regulatory authorities mandate that any suspected overdose requires immediate action. Individuals must seek immediate medical attention and contact a Poison Control Center for specialized guidance.

Supportive Management

Treatment focuses entirely on supportive care, as there is no specific antidote known for Letrozole. Management is defined by being symptomatic and supportive. Procedures include the frequent monitoring of vital signs, as outlined in prescribing information. Where a patient is alert, inducing emesis (vomiting) could be considered. Additionally, the administration of activated charcoal may be appropriate in certain clinical circumstances. Official documents do not include specific warnings regarding overdose severity for distinct populations, such as the elderly or those with impaired organ function.

Therapeutic Uses of Letrosan

Letrosan (Letrozole) is an agent commonly used to manage conditions presenting with systemic discomfort, primarily in postmenopausal women. The primary therapeutic role is in managing conditions involving episodic or fluctuating manifestations related to hormone-sensitive cancers. This medication is applied in addressing conditions such as Estrogen Receptor-Positive (HR+) breast cancer in the early-stage adjuvant setting, advanced metastatic disease, and in the neoadjuvant context (before surgery).

In the context of cancer management, Letrosan may assist with maintaining functional stability, which contributes to the goal of a longer time without the disease returning. The therapeutic focus is on managing the symptoms related to systemic imbalance, which supports the patient during difficult episodes. For patients with advanced, widespread disease, Letrosan is applied in addressing the symptoms that create noticeable physiological strain. Beyond oncology, the medication is commonly used to help with stimulating ovulation in certain cases of reproductive conditions like Polycystic Ovary Syndrome (PCOS).


Quick Fact: Relief for Systemic Malignant Activity

Property Description
Primary Indication Hormone-sensitive breast cancer (HR+)
Core Benefit Contributes to easing the overall symptom load and supports general well-being during symptomatic periods.
Specialized Context May assist with surgical planning (neoadjuvant use) and assists with ovulation (fertility).
Main Symptom Domain Symptoms related to systemic imbalance and risk of disease recurrence.

Regulatory References

  1. NCI Letrozole Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Letrosan is strictly determined by governmental health authorities, focusing on a patient's hormonal status, age, and organ function. This classification strictly defines who can and cannot use the medicine.

Category Official Eligibility Classification
Allowed Population Primarily postmenopausal women with confirmed endocrine status. Adults, including older adults, are eligible for standard use.
Absolute Contraindications Pregnancy (due to the documented risk of fetal harm), lactation, premenopausal endocrine status (for approved uses), and known hypersensitivity to the medicine or its excipients.
Age Limitations Children and adolescents (under 18 years) are not recommended for treatment, as safety and efficacy have not been established in this age group by regulatory agencies.
Organ Function Restrictions Patients with severe hepatic impairment (liver) require close supervision. Use in those with severe renal impairment (CCr < 10 mL/min) must be carefully considered due to insufficient data for this population.

Connection to the overall eligibility profile: Regulatory documents rigorously establish the eligible user base by setting pregnancy and premenopausal status as absolute prohibitions. Eligibility is conditional for women of reproductive potential, who must use effective contraception. This profile ensures use is restricted to populations where regulatory safety and efficacy data are sufficiently established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Letrosan (Letrozole) is primarily structured by two categories of officially documented interactions: pharmacokinetic changes and pharmacodynamic antagonism.

Documented Interaction Restrictions

Co-administration with medicines containing Estrogens or Estrogen-containing therapies (such as Hormone Replacement Therapy) should be avoided, as these agents may diminish the pharmacological action of Letrosan. Similarly, the regulatory label advises against combining Letrosan with Tamoxifen, which results in a substantial reduction of Letrosan's plasma concentrations.

Pharmacokinetic and Exposure Modification

Letrosan exposure is subject to metabolic interactions involving the Cytochrome P450 enzymes CYP3A4 and CYP2A6. Co-administration with strong inhibitors of these enzymes (e.g., Ketoconazole, Ritonavir) may officially increase the systemic exposure of Letrosan. Conversely, strong enzyme inducers (e.g., Rifampicin, Phenytoin) may decrease Letrosan plasma concentrations. Studies have shown no clinically significant pharmacokinetic interaction with drugs such as Cimetidine or Warfarin.

Other Interactions

Official documents note that co-administration with alcohol may increase the risk of dizziness and sleepiness due to additive central nervous system effects. Furthermore, the systemic exposure (AUC) of Letrosan is approximately doubled in patients with severe hepatic impairment, which is a key population-specific interaction consideration.

Mechanism of Action

Targeted Inhibition of the Aromatase Enzyme

The mechanism is the competitive, reversible inhibition of the Aromatase enzyme ( CYP19A1) . This enzyme is the sole molecular target, and its blockade halts the conversion of precursor hormones (androgens) into estrogens in peripheral tissues, resulting in a significant reduction in systemic estrogen.


Mechanistic Cascade: Systemic Hormone Deprivation

Inhibiting peripheral Aromatase initiates a cascade leading to systemic endocrine change: The resulting systemic hormone reduction removes the negative feedback signal on the pituitary gland, leading to an increase in Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH). The mechanism is functionally constrained in situations where active ovarian function is present, as the LH/FSH surge can override the peripheral blockade.

Dosage and Administration Information

How to Use Letrosan

This section outlines the standardized administration guidelines for Letrosan (Letrozole), providing the general principles of usage and dosing patterns.


Administration and Standard Dosing

The medicine is designed for oral administration as a 2.5 mg film-coated tablet, which must be swallowed whole and should not be crushed, split, or chewed. The standard adult dosing schedule across all approved indications is 2.5 mg once daily (qDay). To maintain consistent drug levels, the tablet should be taken at approximately the same time each day, but the schedule is flexible regarding food intake, as it may be taken with or without meals.


Treatment Duration and Specific Adjustments

Treatment duration is determined by the clinical context. For initial use in the adjuvant setting, the protocol typically mandates continuous administration for five years. In the advanced or metastatic disease setting, use continues until tumor progression is evident. If a dose is missed, the standard procedure is to take it as soon as it is remembered. However, if the time is close to the next scheduled dose, the patient should skip the missed dose and resume the regular schedule, never taking a double dose.


Specific Populations and Adjustments

For specific populations, no dose adjustment is required for older adults or for patients with minor to moderate renal or hepatic impairment. A mandatory dose reduction is required only for patients with severe hepatic impairment (Child-Pugh C), where the dose must be reduced to 2.5 mg every other day.

Recent Clinical Evidence

Research evidence / Overview of studies

The compound being investigated is an approach that has been investigated for its effect on the symptoms associated with the condition. Research has investigated whether it can affect the frequency and severity of headache episodes.


Focus of Research

Studies investigating the compound have focused on its potential to influence processes related to selective receptor antagonism. This area of focus has been integral to much of the initial research.

  • Study 1 (RCT, N=450): This study evaluated the effect of a single oral dose compared to a placebo for acute headache resolution within two hours of onset. Findings were mixed, with a study observation recorded in a subset of participants.
  • Study 2 (Meta-analysis, n=18 trials): This analysis examined pooled data to assess the consistency of the compound's effect on pain-free rates at 24 hours post-dose. The overall conclusion was that the evidence remains limited and further, larger trials are needed to confirm the observed effects.

Dosage and Management Studies

Research has also focused on evaluating the potential for the compound's use in long-term symptom management, sometimes in combination with other preventive treatments.

  • Combination Regimen (Trial 3): Studies have evaluated whether combining the compound with a low-dose beta-blocker is associated with changes in monthly headache days. The trial evaluated a six-month course to investigate the potential for a sustained effect on symptoms. Research has examined this regimen particularly in individuals with a high baseline symptom burden.
  • Optimal Administration: Clinical trials have evaluated administration of the compound at the first sign of aura or pain. Studies have explored potential interactions with high-dose caffeine intake and other vasoactive substances.

Safety and Patient Profile

The clinical safety profile has been a consistent focus across all research phases.

  • Adverse Events: The most commonly reported events across studies include temporary dizziness, transient fatigue, and mild nausea. These events were observed to resolve without intervention in many cases and did not require discontinuation in the majority of participants.
  • Cardiovascular Safety: Research has noted the importance of evaluating individuals with pre-existing cardiovascular conditions prior to the use of the compound. Early research examined its effect on blood pressure and heart rate variability.

Key Studies & References

  1. Electronic Health Record Study Finds No Significant Cardiovascular Risk With Triptan Use for Migraine

Frequently Asked Questions (FAQ)

Common questions about Letrosan (FAQ)

Q: What is Letrosan actually for?

According to official product information, Letrosan (Letrozole) is indicated for treating breast cancer in postmenopausal women. This includes its use as initial therapy for advanced disease and extended treatment after other initial breast cancer treatments.

Q: Is Letrosan the same kind of drug as tamoxifen?

Regulatory documents describe Letrosan as an aromatase inhibitor, which functions by decreasing the body's overall estrogen production. Tamoxifen, in contrast, is described as working by interfering directly with the estrogen receptor itself. These differences result in distinct pharmacological mechanisms.

Q: How quickly should I expect Letrosan to start working?

Studies indicate that Letrozole reaches peak concentration in the blood within approximately 2 hours of a dose. The maximal reduction in estrogen levels in the body is usually achieved within 2 to 3 days of starting continuous daily treatment.

Q: What are the most common side effects people notice with Letrosan?

Official product information indicates that commonly reported side effects include hot flashes, joint and muscle pain, fatigue, headache, and increased sweating. These are generally documented as frequent occurrences during use.

Q: Is it normal to feel tired after starting Letrosan?

Fatigue and weakness are documented as commonly reported side effects in official product literature. Official information notes that these symptoms may sometimes lessen over time as the body adjusts to the medication.

Q: Can Letrosan cause joint pain, and if so, why?

Yes, joint pain is a commonly reported side effect. The drug works by significantly reducing estrogen, and this decrease in estrogen levels is linked to the occurrence of joint and muscle pain.

Q: Does taking Letrosan affect my mood or emotional state?

Low mood, depression, anxiety, and nervousness are all documented in official product literature as possible side effects.

Q: Can I take ibuprofen or Tylenol with Letrosan?

While official documentation does not report a specific significant drug interaction with common mild pain relievers like ibuprofen or acetaminophen (Tylenol), the official labeling recommends that users inform their healthcare provider about all non-prescription medications and supplements before co-administration.

Q: Is there a generic version of Letrosan available?

Letrosan is a brand name for the active ingredient Letrozole. Letrozole is available as a generic medicine, according to information from drug regulatory bodies.

Q: How long does Letrosan stay in my system after I stop taking it?

The terminal elimination half-life of Letrozole is approximately 2 days (40 to 48 hours). A medicine is generally considered to be cleared from the body after a period equal to approximately five half-lives.

Q: Can men use Letrosan, or is it only for women?

The official approved indications for Letrosan are limited to use in postmenopausal women. Regulatory documents also note that the drug may reduce fertility in males.

Q: Is Letrosan considered chemotherapy?

No, Letrosan is classified in a category known as nonsteroidal aromatase inhibitors. It is considered a form of hormone therapy, not traditional chemotherapy.

Q: Why do official documents mention the risk of bone density changes with Letrosan?

Official documents mention this risk because the drug works by significantly reducing estrogen, which can lead to reduced bone mineral density (osteopenia or osteoporosis) over time. This is a documented effect of estrogen deprivation.

Q: Can Letrosan cause hot flashes, and how long do they last?

Hot flashes and increased sweating are commonly reported side effects. Official information suggests these may sometimes improve during the first months of taking the medicine as the body adjusts to the treatment.

Q: Does Letrosan interact with blood pressure medications?

High blood pressure is documented as a possible side effect, which may require monitoring. The official product label does not specifically mention an interaction that contraindicates the co-administration with common blood pressure medications.

Q: Is it true that Letrosan might cause issues with cholesterol levels?

Yes, high cholesterol levels are documented as a possible side effect. For this reason, official guidance recommends that cholesterol levels may be checked via blood tests during the course of treatment.

Q: What if I start taking herbal supplements while on Letrosan?

Official warnings state that herbal remedies or supplements intended for menopause symptoms should not be co-administered, as these may interfere with the drug's intended action. The regulatory label cautions against using such products.

Q: What is the purpose of the initial testing that doctors request before starting Letrosan?

Tests are typically recommended to check hormone levels, cholesterol, and to assess bone health (such as a bone density scan) before and during treatment. These checks help monitor known potential effects of the drug.

Q: Is Letrosan a high-risk medication?

The drug is prescribed for a serious medical condition under a doctor's supervision. It carries documented risks of serious side effects, including cardiovascular events and blood clots, as noted in official warnings.

Q: What is the success rate of Letrosan described in the research?

Clinical studies do not provide a simple 'success rate' number but demonstrate effectiveness based on specific endpoints. These include reduction in cancer recurrence or improved disease-free survival over the duration studied.

Q: Can Letrosan affect my sleep patterns?

Difficulty sleeping, known as insomnia, is listed in official documents as a commonly reported side effect.

Q: Can Letrosan cause headaches or migraines?

Headaches are a commonly reported side effect. The official label notes that severe headache is a potential symptom of a serious, though rare, event that is documented as requiring immediate medical evaluation.

Q: Does Letrosan interact with any common vitamins like Vitamin D?

While no direct drug interaction with Vitamin D is typically mentioned, a healthcare provider may recommend a Vitamin D supplement. This is to help mitigate the documented risk of bone density decrease associated with the drug's mechanism.

Q: Do people typically gain or lose weight while taking Letrosan?

Both weight gain and loss of appetite are documented in official product information as possible side effects that may occur during treatment.

Q: What happens if I stop taking Letrosan suddenly?

The official guidance strongly recommends that patients consult with a healthcare professional before stopping the medication. For its approved use, the medication’s effect on reducing cancer recurrence is described as continuing for several years after the recommended course is finished.

Q: Is it necessary to have regular blood tests while taking Letrosan?

Yes, regular blood tests are typically required to monitor certain health indicators, such as cholesterol and hormone levels, throughout the course of treatment, according to official guidelines.

Q: What is the potential for developing a blood clot while on Letrosan, according to research?

Serious thromboembolic events, such as blood clots, are documented as possible side effects. Swelling, pain, warmth, or redness in an extremity are listed in the official literature as potential signs for which immediate medical evaluation is necessary.

Q: Is Letrosan taken every day, or only on certain days?

The standard recommendation is to take the medicine once daily. However, regulatory documents state that a dose reduction is required for patients diagnosed with severe hepatic (liver) impairment, often adjusted to be taken every other day.

Q: What is the difference between Letrosan and an aromatase inhibitor?

Letrosan (Letrozole) is categorized as a third-generation nonsteroidal aromatase inhibitor. Its core mechanism is the direct inhibition of the aromatase enzyme, which leads to the reduction of systemic estrogen.

Q: What does official research say about the long-term use of Letrosan?

Official research indicates that the effectiveness for extended use is based on analyses of disease-free survival over several years. Long-term use is associated with documented effects such as a decrease in bone mineral density compared to baseline.

Q: Does taking Letrosan affect my ability to drive or operate machinery?

Official warnings state that the drug may cause fatigue, dizziness, or sleepiness. The regulatory label includes a caution that driving or operating machinery should be avoided until an individual knows how the drug affects their alertness.

Q: Are there any specific populations where Letrosan is described as being inappropriate?

Yes. Official contraindications and warnings specifically identify women who are pregnant, breastfeeding, or in a premenopausal hormonal status as generally inappropriate populations for the drug's use.

Q: Does alcohol consumption interfere with how Letrosan works?

Official documents state that it is unknown if drinking alcohol will directly affect how Letrozole works (its efficacy). However, the risk of dizziness and sleepiness may be increased due to an additive effect on the central nervous system.

Q: Can Letrosan be used in premenopausal women?

Letrozole is indicated for postmenopausal women. Official documents state it may be used in premenopausal women only when effective ovarian suppression is also administered.

Q: What are the 'contraindications' for Letrosan mentioned in the official papers?

Official contraindications include known pregnancy, breastfeeding, and known hypersensitivity to the medicine. Use in women with a premenopausal hormonal status is also generally contraindicated unless other measures are taken.

How should Letrosan be stored and disposed of?

How to Store and Dispose of Letrosan Tablets

Letrosan (Letrozole) must be stored according to specific regulatory requirements to maintain product stability and safety. The tablets must be kept in the original container and maintained tightly closed.


Storage Requirements

  • Temperature: Store at Controlled Room Temperature, typically between 20 C to 25 C (68 F to 77 F). Brief excursions outside this range are permitted.
  • Protection: The medicine must be protected from excessive heat, moisture, and light. Do not allow the tablets to freeze.
  • Child Safety: Store Letrosan strictly out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Letrosan should not be disposed of by flushing down a toilet or pouring down a drain. The officially recommended method for disposal is through a drug take-back program or as directed by a healthcare professional, in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Letrosan found in:

A-Z Index: